Clinical Trial Search

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF

Primary: Kinematics — 15.5; 10 degrees

Primary: Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test — 1.2; 7.5; 9.7; 6.9 percent change

Primary: Assess the Effect of NBT-NM108 on Serum TNF-alpha Levels in MS Patients — 25.62; 22.58; 20.73 pg/ml

Primary: Number of Adverse Events Assessed by CTCAE v4.0 — 5; 0 total events

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: No.of Gd+ Lesions From Week 8 to Week 24 — 46; 33; 5; 13 participants — p=0.04

Primary: Modified Fatigue Impact Scale — 46.1; 46.7 units on a scale — p=.64

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Proportion of Subjects That Experience a Relapse — 0.32; 0.34 proportion of participants — p=0.60

Primary: Fatigue — 21; 24 % decline

Primary: Safety and Tolerability — 21; 22 participants

Primary: Neuro-cognitive Competence in Daily Living - California Verbal Learning Test-II — 56.1; 53.6 units on a scale — p=0.926

Primary: Walking Endurance — 42; 25 meters

Primary: Peak Activity Index — 0.6; 0.3 change in strides per minute — p=0.586

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci

Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003

Primary: Adherence — 2; 6; 10; 12 Participants

Primary: Annualized Relapse Rate [ARR]: Poisson Regression Estimates — 0.539; 0.370; 0.369 relapses per year — p=0.0005

Primary: Event-Free Survival Probability During the 5 Years After Transplant — 0.692 Probability

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672

Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale

Primary: Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression Estimate — 0.501; 0.389; 0.319 relapses per year — p=0.0001

Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51

Primary: Distance Walked on a Treadmill With tDCS — 375; 285 m

Primary: Exercise Duration — 42.2; 42.2 Minutes

Primary: Expanded Disability Status Score — 2.9; 2.6 score on a scale